These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 4272745)

  • 21. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification.
    Cichewicz DL; Martin ZL; Smith FL; Welch SP
    J Pharmacol Exp Ther; 1999 May; 289(2):859-67. PubMed ID: 10215664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of delta9-tetrahydrocannabinol and ethanol on body weight protein and nucleic acid synthesis in chick embryos.
    Jakubović A; McGeer PL
    J Toxicol Environ Health; 1976 Jan; 1(3):441-7. PubMed ID: 1246086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerance to the reinforcing effects of morphine in delta9-tetrahydrocannabinol treated mice.
    Jardinaud F; Roques BP; Noble F
    Behav Brain Res; 2006 Oct; 173(2):255-61. PubMed ID: 16884789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Some kinetic and inhibition properties of human brain mitochondrial monoamine oxidase (EC 1.4.3.4).
    Jain M; Bakutis E; Gayle T; Lansky P
    Neurobiology; 1974; 4(3):180-90. PubMed ID: 4367441
    [No Abstract]   [Full Text] [Related]  

  • 25. Asymmetrical effect of delta-9-tetrahydrocannabinol (THC) on striatal dopamine and behavior.
    Waters DH; Glick SD
    Res Commun Chem Pathol Pharmacol; 1973 Jul; 6(1):57-63. PubMed ID: 4734017
    [No Abstract]   [Full Text] [Related]  

  • 26. Delta9-tetrahydrocannabinol and 11-hydroxy-delta9-tetrahydrocannabinol: behavioral effects and tolerance development.
    Kosersky DS; McMillan DE; Harris LS
    J Pharmacol Exp Ther; 1974 Apr; 189(1):61-5. PubMed ID: 4823300
    [No Abstract]   [Full Text] [Related]  

  • 27. Anticonvulsant activity of delta9-tetrahydrocannabilol and its 11-hydroxy and 8alpha, 11-dihydroxy metabolites in the frog.
    Karler R; Cely W; Turkanis SA
    Res Commun Chem Pathol Pharmacol; 1974 Nov; 9(3):441-52. PubMed ID: 4548551
    [No Abstract]   [Full Text] [Related]  

  • 28. On the action of delta 9-tetrahydrocannabinol as an inhibitor of sodium- and potassium-dependent adenosine triphosphatase.
    Toro-Goyco E; Rodréguez MB; Preston AM
    Mol Pharmacol; 1978 Jan; 14(1):130-7. PubMed ID: 146821
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug impairment reviews: marihuana, general hallucinogens.
    Moskowitz H
    NIDA Res Monogr; 1977 Mar; Series 11():77-90. PubMed ID: 408694
    [No Abstract]   [Full Text] [Related]  

  • 30. [Hashish and LSD. Physical and mental effects. 2].
    Remschmidt H
    Med Klin; 1972 Jun; 67(22):781-6. PubMed ID: 4557613
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative pharmacology of Delta9-tetrahydrocannabinol and its metabolite, 11-OH-Delta9-tetrahydrocannabinol.
    Lemberger L; Martz R; Rodda B; Forney R; Rowe H
    J Clin Invest; 1973 Oct; 52(10):2411-7. PubMed ID: 4729039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pharmacological and conceptual reevaluation of hallucinations.
    Fischer R
    Confin Psychiatr; 1974; 17(3-4):143-51. PubMed ID: 4465066
    [No Abstract]   [Full Text] [Related]  

  • 33. [Cannabis and car driving].
    Retterstol N
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2121-2. PubMed ID: 4773988
    [No Abstract]   [Full Text] [Related]  

  • 34. Toxicology of marihuana.
    Forney RB
    Pharmacol Rev; 1971 Dec; 23(4):279-84. PubMed ID: 4943946
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of cannabis extract, 9 -tetrahydrocannabinol and lysergic acid diethylamide on rat liver enzymes.
    Poddar MK; Ghosh JJ
    Biochem Pharmacol; 1972 Dec; 21(24):3301-3. PubMed ID: 4405370
    [No Abstract]   [Full Text] [Related]  

  • 36. Sodium-potassium-activated adenosine triphosphatase activity as a measure of neuronal membrane characteristics in ethanol-tolerant mice.
    Levental M; Tabakoff B
    J Pharmacol Exp Ther; 1980 Feb; 212(2):315-9. PubMed ID: 6243362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of delta9-THC, LSD-25 and scopolamine on continuous, spontaneous alternation in the Y-maze.
    Drew WG; Miller LL; Baugh EL
    Psychopharmacologia; 1973; 32(2):171-82. PubMed ID: 4753532
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of delta9-tetrahydrocannabinol on the metabolism of 3H-5-hydroxytryptamine and 3H-norepinephrine in the rat brain.
    Ho BT; Taylor D; Englert LF
    Res Commun Chem Pathol Pharmacol; 1974 Apr; 7(4):645-50. PubMed ID: 4828760
    [No Abstract]   [Full Text] [Related]  

  • 39. [Dependent behavior. Pharmacologic aspects of drugs].
    Kutsch Lojenga JC
    Ned Tijdschr Geneeskd; 1978 Oct; 122(40):1509-11. PubMed ID: 211451
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of a delta9-tetrahydrocannabinol (delta9-THC) metabolite on bone marrow myelopoiesis.
    Johnson RJ; Wiersema V
    Res Commun Chem Pathol Pharmacol; 1974 Jun; 8(2):393-6. PubMed ID: 4851725
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.